Meet the Blood Cancer Taskforce: Dr Rishi Kotecha
Meet Dr Rishi, a Consultant Paediatric Oncologist & Clinical Haematologist.
- Advocacy and policy
Tag: Advocacy and policy
Decisions from the March PBAC meeting for CLL/SLL
Acalabrutinib (Calquence®) will be added to the therapy arsenal for CLL and SLL.
- Advocacy and policy
- Chronic lymphocytic leukaemia
- Other blood cancers
- Treatments and side-effects
Government announces incentive to help meet shortfall in charitable donations due to COVID-19
- Advocacy and policy
- Media releases
- Our supporters
Precision treatment for all young Australians living with blood cancer
- Advocacy and policy
- Media releases
Treatment for more Australians living with myeloma now available through Pharmaceutical Benefits Scheme (PBS)
- Advocacy and policy
- Media releases
- Myeloma
PBAC reconsidered plitidepsin for myeloma 
The Pharmaceutical Benefits Advisory Committee (PBAC) considered four blood cancer treatments at its March 2020 meeting including a drug for myeloma – plitidepsin (Aplidin®).
- Advocacy and policy
- Myeloma
- Treatments and side-effects
Number of Australians living with blood cancer to more than double
- Advocacy and policy
- Media releases
Government’s commitment to blood cancer
The Leukaemia Foundation welcomes the commitment from the Federal Health Minister Greg Hunt to establish a Blood Cancer Taskforce and Action Plan.
- Advocacy and policy
- Media releases
National blood cancer taskforce meets
- Advocacy and policy
- Media releases
Leukaemia Foundation supports latest Pharmaceutical Benefits Scheme (PBS) listings for blood cancer patients
- Advocacy and policy
- Media releases